Kristen Ganjoo

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint The treatment outcome for adult patients with Ewing's sarcoma
    Kristen N Ganjoo
    Department of Medicine, Division of Oncology, Stanford Comprehensive Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Curr Oncol Rep 15:372-7. 2013
  2. ncbi request reprint The prognostic value of tumor-associated macrophages in leiomyosarcoma: a single institution study
    Kristen N Ganjoo
    Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA, 94305, USA
    Am J Clin Oncol 34:82-6. 2011
  3. doi request reprint New developments in targeted therapy for soft tissue sarcoma
    Kristen N Ganjoo
    Stanford University, 269 Campus Drive, Stanford, CA 94305, USA
    Curr Oncol Rep 12:261-5. 2010
  4. doi request reprint A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma
    Kristen N Ganjoo
    Stanford University Medical Center, Stanford, Calif, USA
    Oncology 80:50-6. 2011
  5. doi request reprint Current and emerging pharmacological treatments for gastrointestinal stromal tumour
    Kristen N Ganjoo
    Department of Medicine, Division of Oncology, Stanford Comprehensive Cancer Center, Stanford, California, USA
    Drugs 71:321-30. 2011
  6. doi request reprint Antiangiogenesis agents in the treatment of soft tissue sarcomas
    Kristen Ganjoo
    Division of Oncology, Stanford University, Palo Alto, CA, USA
    Cancer 116:1177-83. 2010
  7. doi request reprint Trabectedin: an anticancer drug from the sea
    Kristen N Ganjoo
    Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Expert Opin Pharmacother 10:2735-43. 2009
  8. ncbi request reprint The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients
    Kristen N Ganjoo
    Division of Oncology, Stanford University, Stanford, CA, USA
    J Cancer Res Clin Oncol 134:381-7. 2008
  9. ncbi request reprint Non-Hodgkin lymphoma of the breast
    Kristen Ganjoo
    Department of Medical Oncology, Stanford University, Stanford, California, USA
    Cancer 110:25-30. 2007
  10. ncbi request reprint Antiangiogenesis: a new approach to the treatment of lymphoma
    Kristen Ganjoo
    Department of Medicine Oncology, Stanford University, Palo Alto, CA 94304, USA
    Leuk Lymphoma 48:454-5. 2007

Detail Information

Publications19

  1. doi request reprint The treatment outcome for adult patients with Ewing's sarcoma
    Kristen N Ganjoo
    Department of Medicine, Division of Oncology, Stanford Comprehensive Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Curr Oncol Rep 15:372-7. 2013
    ..In this article, we will review the primary treatment for adult patients with Ewing's sarcoma, both for localized and metastatic disease. The prognostic factors in adult patients with EWS will also be reviewed. ..
  2. ncbi request reprint The prognostic value of tumor-associated macrophages in leiomyosarcoma: a single institution study
    Kristen N Ganjoo
    Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA, 94305, USA
    Am J Clin Oncol 34:82-6. 2011
    ..The purpose of this study is to evaluate the outcome of patients with LMS from a single institution according to the number of TAMs evaluated through 3 CSF1 associated proteins...
  3. doi request reprint New developments in targeted therapy for soft tissue sarcoma
    Kristen N Ganjoo
    Stanford University, 269 Campus Drive, Stanford, CA 94305, USA
    Curr Oncol Rep 12:261-5. 2010
    ....
  4. doi request reprint A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma
    Kristen N Ganjoo
    Stanford University Medical Center, Stanford, Calif, USA
    Oncology 80:50-6. 2011
    ..Patients and..
  5. doi request reprint Current and emerging pharmacological treatments for gastrointestinal stromal tumour
    Kristen N Ganjoo
    Department of Medicine, Division of Oncology, Stanford Comprehensive Cancer Center, Stanford, California, USA
    Drugs 71:321-30. 2011
    ..The duration of adjuvant therapy is currently under evaluation; however, it is possible that these patients would need to continue therapy indefinitely...
  6. doi request reprint Antiangiogenesis agents in the treatment of soft tissue sarcomas
    Kristen Ganjoo
    Division of Oncology, Stanford University, Palo Alto, CA, USA
    Cancer 116:1177-83. 2010
    ..In addition, the authors conducted an in-depth review of the results from using key antiangiogenesis agents in the treatment of STS...
  7. doi request reprint Trabectedin: an anticancer drug from the sea
    Kristen N Ganjoo
    Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Expert Opin Pharmacother 10:2735-43. 2009
    ..Trabectedin (ET-743) is an anticancer agent originally isolated from Ecteinascidia turbinata, a marine organism...
  8. ncbi request reprint The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients
    Kristen N Ganjoo
    Division of Oncology, Stanford University, Stanford, CA, USA
    J Cancer Res Clin Oncol 134:381-7. 2008
    ..This is a single institution retrospective study evaluating the role of angiogenesis markers in the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL)...
  9. ncbi request reprint Non-Hodgkin lymphoma of the breast
    Kristen Ganjoo
    Department of Medical Oncology, Stanford University, Stanford, California, USA
    Cancer 110:25-30. 2007
    ..A retrospective study was done to evaluate the institutional experience in this patient population...
  10. ncbi request reprint Antiangiogenesis: a new approach to the treatment of lymphoma
    Kristen Ganjoo
    Department of Medicine Oncology, Stanford University, Palo Alto, CA 94304, USA
    Leuk Lymphoma 48:454-5. 2007
  11. ncbi request reprint Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis
    Kristen N Ganjoo
    Department of Medicine Oncology, Stanford University, CA, USA
    Leuk Lymphoma 47:998-1005. 2006
    ..In this patient population, treatment with RA-CHOP did not result in any episodes of grade 3 or 4 proteinuria, heart failure or hemorrhage. The RA-CHOP combination was generally well tolerated and safe...
  12. doi request reprint Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer
    Jonathan W Riess
    Division of Hematology, Department of Medicine, Stanford University School of Medicine, CA, USA
    Cancer Invest 30:231-5. 2012
    ..268 days, p =.38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients...
  13. ncbi request reprint Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome
    Eve Henry
    Department of Medicine, Stanford University, Stanford, California, USA
    J Natl Compr Canc Netw 10:939-42. 2012
    ....
  14. pmc Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor
    Rondeep Brar
    Department of Internal Medicine, Stanford University Medical Center, Stanford, Calif, USA
    Case Rep Oncol 2:242-250. 2009
    ..CONCLUSION: Angiosarcoma of the breast is an aggressive malignancy with a propensity for both local recurrence and distant metastases. Angiogenesis inhibition may represent a novel therapeutic modality in this rare, vascular malignancy...
  15. pmc Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study
    Brad S Kahl
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Cancer 116:106-14. 2010
    ..Bendamustine hydrochloride is a novel alkylating agent. In this multicenter study, the authors evaluated the efficacy and toxicity of single-agent bendamustine in patients with rituximab-refractory, indolent B-cell lymphoma...
  16. doi request reprint A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer
    Christelle Clément-Duchêne
    Division of Oncology, Department of Medicine, Department of Biostatistics, Stanford Cancer Center, Stanford University, Stanford, California 94305 5826, USA
    J Thorac Oncol 5:1821-5. 2010
    ..This study was designed to evaluate toxicities and efficacy of gemcitabine/carboplatin/bevacizumab...
  17. ncbi request reprint Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)
    Kristen Ganjoo
    Stanford University, Stanford, CA, USA
    Leuk Lymphoma 55:768-72. 2014
    ..Studies of novel therapeutics are needed for this patient population, whose clinical outcome remains poor...
  18. ncbi request reprint Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia
    Arthur E Frankel
    Department of Medicine, Scott and White Hospital, Temple, Texas 76508, USA
    Cancer 106:2158-64. 2006
    ....
  19. doi request reprint 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
    Mol Imaging Biol 12:198-203. 2010
    ..Both target CD20 receptors present on the surface of lymphocytes. We present our clinical experience with Bexxar and Zevalin in the management of low-grade refractory or relapsed NHL...